Sublingual dexmedetomidine for treatment of agitation in bipolar disorder.

Randomized Placebo controlled trial reported in JAMA demonstrated effectiveness over placebo at 2 hours. The medication was well tolerated.
Not clear if the clinical effect is sufficient.

Preskorn SH, Zeller S, Citrome L, et al. Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial. JAMA. 2022;327(8):727–736. doi:10.1001/jama.2022.0799

Joseph (Joe) E. Thornton, M.D., DFAPA

Published by Joseph Thornton MD

Teacher, Clinical Supervisor Clinical Associate Professor, Psychiatry University of Florida Affiliation is for identification only. All content and opinions are my own.

Leave a comment